• Je něco špatně v tomto záznamu ?

Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe

C. Keppens, JF. Palma, PM. Das, S. Scudder, W. Wen, N. Normanno, JH. van Krieken, A. Sacco, F. Fenizia, D. Gonzalez de Castro, S. Hönigschnabl, I. Kern, F. Lopez-Rios, MD. Lozano, A. Marchetti, P. Halfon, E. Schuuring, U. Setinek, B. Sorensen, P....

. 2018 ; 20 (4) : 483-494. [pub] 20180426

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035276

Molecular testing of EGFR is required to predict the response likelihood to targeted therapy in non-small cell lung cancer. Analysis of circulating tumor DNA in plasma may complement limitations of tumor tissue. This study evaluated the interlaboratory performance and reproducibility of a real-time PCR EGFR mutation test (cobas EGFR Mutation Test v2) to detect EGFR variants in plasma. Fourteen laboratories received two identical panels of 27 single-blinded plasma samples. Samples were wild type or spiked with plasmid DNA to contain seven common EGFR variants at six predefined concentrations from 50 to 5000 copies per milliliter. The circulating tumor DNA was extracted by a cell-free circulating DNA sample preparation kit (cobas cfDNA Sample Preparation Kit), followed by duplicate analysis with the real-time PCR EGFR mutation test (Roche Molecular Systems, Pleasanton, CA). Lowest sensitivities were obtained for the c.2156G>C p.(Gly719Ala) and c.2573T>G p.(Leu858Arg) variants for the lowest target copies. For all other variants, sensitivities varied between 96.3% and 100.0%. All specificities were 98.8% to 100.0%. Coefficients of variation indicated good intralaboratory and interlaboratory repeatability and reproducibility but increased for decreasing concentrations. Prediction models revealed a significant correlation for all variants between the predefined copy number and the observed semiquantitative index values, which reflect the samples' plasma mutation load. This study demonstrates an overall robust performance of the real-time PCR EGFR mutation test kit in plasma. Prediction models may be applied to estimate the plasma mutation load for diagnostic or research purposes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035276
003      
CZ-PrNML
005      
20191015114554.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jmoldx.2018.03.006 $2 doi
035    __
$a (PubMed)29704571
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Keppens, Cleo $u Department of Public Health and Primary Care, Biomedical Quality Assurance Research Unit, University of Leuven, Leuven, Belgium.
245    10
$a Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe / $c C. Keppens, JF. Palma, PM. Das, S. Scudder, W. Wen, N. Normanno, JH. van Krieken, A. Sacco, F. Fenizia, D. Gonzalez de Castro, S. Hönigschnabl, I. Kern, F. Lopez-Rios, MD. Lozano, A. Marchetti, P. Halfon, E. Schuuring, U. Setinek, B. Sorensen, P. Taniere, M. Tiemann, H. Vosmikova, EMC. Dequeker,
520    9_
$a Molecular testing of EGFR is required to predict the response likelihood to targeted therapy in non-small cell lung cancer. Analysis of circulating tumor DNA in plasma may complement limitations of tumor tissue. This study evaluated the interlaboratory performance and reproducibility of a real-time PCR EGFR mutation test (cobas EGFR Mutation Test v2) to detect EGFR variants in plasma. Fourteen laboratories received two identical panels of 27 single-blinded plasma samples. Samples were wild type or spiked with plasmid DNA to contain seven common EGFR variants at six predefined concentrations from 50 to 5000 copies per milliliter. The circulating tumor DNA was extracted by a cell-free circulating DNA sample preparation kit (cobas cfDNA Sample Preparation Kit), followed by duplicate analysis with the real-time PCR EGFR mutation test (Roche Molecular Systems, Pleasanton, CA). Lowest sensitivities were obtained for the c.2156G>C p.(Gly719Ala) and c.2573T>G p.(Leu858Arg) variants for the lowest target copies. For all other variants, sensitivities varied between 96.3% and 100.0%. All specificities were 98.8% to 100.0%. Coefficients of variation indicated good intralaboratory and interlaboratory repeatability and reproducibility but increased for decreasing concentrations. Prediction models revealed a significant correlation for all variants between the predefined copy number and the observed semiquantitative index values, which reflect the samples' plasma mutation load. This study demonstrates an overall robust performance of the real-time PCR EGFR mutation test kit in plasma. Prediction models may be applied to estimate the plasma mutation load for diagnostic or research purposes.
650    _2
$a algoritmy $7 D000465
650    _2
$a zkreslení výsledků (epidemiologie) $7 D015982
650    _2
$a cirkulující nádorová DNA $x krev $x genetika $7 D000074141
650    _2
$a erbB receptory $x krev $x genetika $7 D066246
650    _2
$a genová dávka $7 D018628
650    _2
$a lidé $7 D006801
650    _2
$a modely genetické $7 D008957
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a kvantitativní polymerázová řetězová reakce $x metody $7 D060888
650    _2
$a senzitivita a specificita $7 D012680
651    _2
$a Evropa $7 D005060
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Palma, John F $u Roche Sequencing Solutions, Pleasanton, California.
700    1_
$a Das, Partha M $u Genomics and Oncology, Roche Molecular Systems, Pleasanton, California.
700    1_
$a Scudder, Sidney $u Genomics and Oncology, Roche Molecular Systems, Pleasanton, California.
700    1_
$a Wen, Wei $u Genomics and Oncology, Roche Molecular Systems, Pleasanton, California.
700    1_
$a Normanno, Nicola $u Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori 'Fondazione G. Pascale'-IRCCS, Naples, Italy.
700    1_
$a van Krieken, J Han $u Department of Pathology, Radboud University Medical Center, Nijmegen, the Netherlands.
700    1_
$a Sacco, Alessandra $u Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori 'Fondazione G. Pascale'-IRCCS, Naples, Italy.
700    1_
$a Fenizia, Francesca $u Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori 'Fondazione G. Pascale'-IRCCS, Naples, Italy.
700    1_
$a Gonzalez de Castro, David $u Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom; The Royal Marsden, Surrey, United Kingdom.
700    1_
$a Hönigschnabl, Selma $u Pathology and Bacteriology, SMZO Donauspital, Vienna, Austria.
700    1_
$a Kern, Izidor $u University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
700    1_
$a Lopez-Rios, Fernando $u Hospital Universitario HM Sanchinarro, Madrid, Spain.
700    1_
$a Lozano, Maria D $u University of Navarra-Clinical University of Navarra, Pamplona, Spain.
700    1_
$a Marchetti, Antonio $u Center of Predictive Molecular Medicine, CeSI-Met, University of Chieti, Chieti, Italy.
700    1_
$a Halfon, Philippe $u Laboratoire Alphabio, Marseille, France.
700    1_
$a Schuuring, Ed $u Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
700    1_
$a Setinek, Ulrike $u Institute for Pathology and Bacteriology, Otto Wagner Spital, Vienna, Austria.
700    1_
$a Sorensen, Boe $u Department of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmark.
700    1_
$a Taniere, Phillipe $u Molecular Pathology Diagnostic Service, Queen Elizabeth Hospital, Birmingham, United Kingdom.
700    1_
$a Tiemann, Markus $u Institut fur Haematopathologie, Hamburg, Germany.
700    1_
$a Vosmikova, Hana $u Faculty Hospital Hradec Kralove, Hradec Králové, Czech Republic.
700    1_
$a Dequeker, Elisabeth M C $u Department of Public Health and Primary Care, Biomedical Quality Assurance Research Unit, University of Leuven, Leuven, Belgium. Electronic address: els.dequeker@kuleuven.be.
773    0_
$w MED00012712 $t The Journal of molecular diagnostics : JMD $x 1943-7811 $g Roč. 20, č. 4 (2018), s. 483-494
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29704571 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191015115020 $b ABA008
999    __
$a ok $b bmc $g 1451936 $s 1073826
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 20 $c 4 $d 483-494 $e 20180426 $i 1943-7811 $m The Journal of molecular diagnostics $n J Mol Diagn $x MED00012712
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace